Call it a new type of precision medicine. A Northeastern researcher says one day oncologists may be able to write ...

Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% ...

Q4 2024 Earnings Call Transcript March 27, 2025 PDS Biotechnology Corporation beats earnings expectations. Reported EPS is ...

PARP7 is a mono-ADP-ribosyl transferase (mono-ART) which has recently gained attention due to its emerging role as a negative ...

New research suggests that a larger waist circumference is a bigger risk factor than body mass index (BMI) for ...

The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory ...

“A lucid dream is when you know you’re dreaming. You can train yourself to control what happens in lucid dreams, but there’s ...

Jyong Biotech Ltd. (Revived IPO) (MENS) is planning to raise $22 million in an initial public offering (IPO) on Thursday, April 3rd, IPO Scoop reports. The company plans to issue 2,700,000 shares at ...

First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer. Initiation of trial sites underway for ground ...

Jyong Biotech Ltd. (Revived IPO) (MENS) expects to raise $22 million in an IPO on Thursday, April 3rd, IPO Scoop reports. The company will be issuing 2,700,000 shares at $7.50-$8.50 per share. The ...

The company’s Phase III trial of nemvaleukin alfa alongside Keytruda saw just a 0.3 month gain in overall survival over other ...

Corvus Pharmaceuticals has faced volatility due to mixed clinical data and given the current valuation and market ...